Drug Trial Radar · NCT06496178
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
621
Actual
Start
Jun 25, 2024
Primary completion
Feb 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
PetosemtamabDrug
MCLA-158
Investigator's ChoiceDrug
Cetuximab
Investigator's ChoiceDrug
Methotrexate
Investigator's ChoiceDrug
Docetaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 3 years
Locations
188 sites in 24 countries. Site status is shown where the registry gives one.
Site 160
Mobile, Alabama
Site 102
Prescott, Arizona
Site 125
Scottsdale, Arizona
Site 82
Duarte, California
Site 25
La Jolla, California
Site 173
Orange, California
Site 28
Palo Alto, California
Site 127
Sacramento, California
Site 46
San Francisco, California
Site 130
Lone Tree, Colorado
Site 104
Washington D.C., District of Columbia
Site 12
Fort Myers, Florida
Site 123
Jacksonville, Florida
Site 9
Orlando, Florida
Site 138
Tampa, Florida
Site 187
Atlanta, Georgia
Site 152
Chicago, Illinois
Site 213
Chicago, Illinois
Site 68
Chicago, Illinois
Site 31
Indianapolis, Indiana
Site 8
Louisville, Kentucky
Site 40
Baton Rouge, Louisiana
Site 100
New Orleans, Louisiana
Site 153
Columbia, Maryland
Site 77
Boston, Massachusetts
Site 103
Ann Arbor, Michigan
Site 5
Detroit, Michigan
Site 49
Maple Grove, Minnesota
Site 124
Rochester, Minnesota
Site 18
St Louis, Missouri
Site 15
Albuquerque, New Mexico
Site 24
New York, New York
Site 214
The Bronx, New York
Site 98
Chapel Hill, North Carolina
Site 122
Durham, North Carolina
Site 23
Cincinnati, Ohio
Site 218
Cleveland, Ohio
Site 87
Cleveland, Ohio
Site 32
Columbus, Ohio
Site 26
Portland, Oregon
Showing 40 of 188 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.